12:00 AM
 | 
Sep 23, 2016
 |  BC Extra  |  Clinical News

J&J six-week combo cures all HCV patients in Phase II cohort

All 20 patients receiving a six-week course of a triple-combination therapy from Johnson & Johnson (NYSE:JNJ) to treat HCV genotype 1 infection achieved an SVR12 in a Phase II study, according to J&J's partners Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) and Medivir AB (SSE:MVIR...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >